Facebook
Twitter
LinkedIn
Forward
Treating TED: More Than Meets the Eye (CE Monograph)
Activity Description and Purpose
This educational activity aims to equip optometrists with advanced knowledge of the diagnosis, individualized treatment planning, and management of thyroid eye disease (TED), highlighting the importance of a collaborative, multidisciplinary care team. Through engaging content delivered by esteemed experts, participants will explore TED diagnostic criteria, the latest clinical data for creating personalized treatment plans, and effective strategies for managing adverse effects such as hyperglycemia and hearing loss associated with insulin-like growth factor-1 receptor antagonists. The educational activity integrates didactics, clinical case studies, and discussion panels, designed to reinforce learning objectives and encourage the application of knowledge in clinical settings. The desired results of this activity are to improve clinicians’ ability to accurately diagnose TED, optimally integrate therapies for TED according to clinical data, identify and manage treatment-related adverse events, and incorporate strategies for fostering multidisciplinary collaboration to ensure the best possible outcomes for patients living with this disease.
Target Audience
This educational activity is intended for optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Review diagnostic criteria that are critical in identifying patients with thyroid eye disease
- Create individualized treatment plans for patients with thyroid eye disease according to the latest clinical data
- Develop strategies for mitigating hyperglycemia and hearing loss in patients with thyroid eye disease receiving insulin-like growth factor 1 receptor antagonists
- Outline the roles and responsibilities of the multidisciplinary care team in thyroid eye disease management
Faculty
 | Andrew G. Lee, MD (Chair) Herb and Jean Lyman Centennial Chair in Ophthalmology Department of Ophthalmology Blanton Eye Institute Professor of Ophthalmology, Neurology, and Neurosurgery Academic Institute Full Clinical Member Research Institute Houston Methodist Weill Cornell Medical College Houston, Texas |
 | Eugene L. Alford, MD, FACS Associate Professor of Otolaryngology and Plastic Surgery Academic Institute Houston Methodist Hospital Weill Medical College of Cornell University Adjunct Professor Texas A&M Intercollegiate College of Medicine (EnMed) Houston, Texas |
 | Victor J. Bernet, MD, FACE, FACP Director Endocrinology, Diabetes and Metabolism Fellowship Program Professor of Medicine Mayo Clinic College of Medicine and Science Mayo Clinic Jacksonville, Florida |
 | Wendy W. Lee, MD, MS Professor of Clinical Ophthalmology and Dermatology Oculofacial Plastic & Reconstructive Surgery, Orbit, and Oncology Bascom Palmer Eye Institute University of Miami Miller School of Medicine Miami, Florida |
 | Joseph Sowka, OD, FAAO Center for Sight Venice, Florida |
 | Prem S. Subramanian, MD, PhD Chief, Neuro-Ophthalmology Clifford R. and Janice N. Merrill Endowed Chair in Ophthalmology Vice Chair for Academic Affairs, Ophthalmology Professor in Ophthalmology, Neurology, and Neurosurgery Sue Anschutz-Rodgers University of Colorado Eye Center University of Colorado School of Medicine Aurora, Colorado |
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.
Faculty
Eugene Alford, MD, has no relevant commercial relationships to disclose.
Victor Bernet, MD, has no relevant commercial relationships to disclose.
Andrew G. Lee, MD, is a consultant for Alexion Pharmaceuticals, Inc, AstraZeneca, Bristol-Myers Squibb, Stoke Therapeutics and Viridian Therapeutics, Inc; and is on the speakers bureau for Amgen Inc.
Wendy W. Lee, MD, MS, is a consultant for AbbVie Inc, Amgen Inc, Mallinckrodt*, Novabay Pharmaceuticals, Inc, Revance Therapeutics, Inc, RVL Pharmaceuticals, Inc*, and Tarsus Pharmaceuticals, Inc; and is a contracted researcher for Viridian Therapeutics, Inc.
Joseph Sowka, OD, is on the speakers bureau for Bausch & Lomb Incorporated.
Prem S. Subramanian, MD, PhD, is a consultant for ACELYRIN, Inc; is an advisory board member of Amgen Inc, GenSight Biologics, Kriya Therapeutics, and Viridian Therapeutics, Inc; and is a contracted researcher for Amgen Inc, Immunovant, Inc, Invex Therapeutics*, Neurophth Therapeutics, Tourmaline Bio, Inc, and Viridian Therapeutics, Inc.
Peer Reviewer
Hadi Kaakour, MD, was formerly an advisory board member of Alimera Sciences*.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
* The financial relationship existed during the past 24 months but has now ended.
Accreditation Statement
COPE approved for 1.5 CE credits for optometrists.
COPE course ID: 91124-SD (Asynchronous)
COPE Course Category: Systemic Disease
Administrator: 
This activity, COPE Activity Number 128309, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus has received commercial support from Amgen Inc for this activity in the form of an unrestricted educational grant.
The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Sponsored by 
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, or Amgen Inc.
This CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 313
Available Credit
- 1.50 COPE